Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation

Purpose: The goal of this study is to identify novel genes frequently silenced by promoter hypermethylation in lung cancer. Experimental Designs: Bioinformatic analysis was done to identify candidate genes significantly down-regulated in lung cancer. The effects of DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine on the expression of the candidate genes were determined. Methylated CpG sites in the promoters of the candidate genes were identified using bisulfite DNA sequencing. Methylation-specific PCR was developed and used to analyze DNA methylation in cell lines and clinical specimen. Pathologic and functional analyses were done to study the role of one candidate gene, receptor activity-modifying protein 2 (RAMP2), in suppressing lung cancer cell growth. Results: Among 54 candidate genes down-regulated in lung cancer, 31 were found to contain CpG islands in their promoters. Six of these 31 genes could be reactivated by 5-aza-2′-deoxycytidine in at least four of six lung cancer cell lines analyzed. Promoter hypermethylation of RAMP2, epidermal growth factor–containing fibulin-like extracellular matrix protein 1, and deleted in U Twenty Twenty cells was detected in 36% to 77% of 22 lung cancer cell lines and in 38% to 50% of 32 primary lung tumors, whereas hypermethylathion of these genes was rarely found in the matched normal samples. The methylation frequencies of these genes in lung cancer were similar to those of commonly used methylation markers, such as RAS association domain family protein 1A, p16, and methylguanine-DNA methyltransferase. Immunohistochemistry showed that RAMP2 was down-regulated in a majority of lung tumors, and RAMP2 down-regulation was correlated with high tumor grade. Ectopic expression of RAMP2 inhibited lung cancer cell growth and caused apoptotic cell death. Knockdown of RAMP2 by RNA interference stimulated cell proliferation. Conclusions: Studying the newly identified genes may provide new insight into lung tumorigenesis. These genes might be useful as molecular markers of lung cancer.

[1]  Jian Yu,et al.  The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage , 2007, Proceedings of the National Academy of Sciences.

[2]  Peng Wang,et al.  PUMA Dissociates Bax and Bcl-XL to Induce Apoptosis in Colon Cancer Cells* , 2006, Journal of Biological Chemistry.

[3]  Jian Yu,et al.  PUMA Sensitizes Lung Cancer Cells to Chemotherapeutic Agents and Irradiation , 2006, Clinical Cancer Research.

[4]  D. Sidransky,et al.  PGP9.5 methylation in diffuse-type gastric cancer. , 2006, Cancer research.

[5]  W. Schiemann,et al.  Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. , 2006, Cancer research.

[6]  W. Gallagher,et al.  Fibulins and cancer: friend or foe? , 2005, Trends in molecular medicine.

[7]  Joachim Diebold,et al.  Functional epigenomics identifies genes frequently silenced in prostate cancer. , 2005, Cancer research.

[8]  S. Burdach,et al.  CpG island methylation and expression of tumour-associated genes in lung carcinoma. , 2005, European journal of cancer.

[9]  K. Kinzler,et al.  SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Rabbitts,et al.  Targeted Disruption of the 3p12 Gene, Dutt1/Robo1, Predisposes Mice to Lung Adenocarcinomas and Lymphomas with Methylation of the Gene Promoter , 2004, Cancer Research.

[11]  S. Belinsky,et al.  Gene-promoter hypermethylation as a biomarker in lung cancer , 2004, Nature Reviews Cancer.

[12]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[13]  H. Kuniyasu,et al.  Alterations of the Dutt1/Robo1 gene in lung adenocarcinomas induced by N‐nitrosobis(2‐hydroxypropyl)amine in rats , 2004, Molecular carcinogenesis.

[14]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[15]  Francis L. Munier,et al.  Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) Is a Binding Partner of Epithelial Growth Factor-containing Fibulin-like Extracellular Matrix Protein 1 (EFEMP1) , 2004, Journal of Biological Chemistry.

[16]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[17]  J. Herman.  Epigenetics in lung cancer: focus on progression and early lesions. , 2004, Chest.

[18]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[19]  J. Crapo,et al.  Superoxide dismutases in the lung and human lung diseases. , 2003, American journal of respiratory and critical care medicine.

[20]  Zhou Wang,et al.  Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo , 2003, Molecular and Cellular Endocrinology.

[21]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[22]  J. Minna,et al.  SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. , 2002, Cancer research.

[23]  J. Minna,et al.  Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers , 2002, Oncogene.

[24]  Kenneth H Buetow,et al.  An anatomy of normal and malignant gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Minna,et al.  Focus on lung cancer. , 2002, Cancer cell.

[26]  Michael Ruogu Zhang,et al.  Molecular characteristics of non-small cell lung cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Rabbitts,et al.  Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[29]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[30]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[31]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[32]  P. Davies.  A Very Incomplete Comprehensive Theory of Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[33]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[34]  J. Jen,et al.  An Overview on the Isolation and Analysis of Circulating Tumor DNA in Plasma and Serum , 2000, Annals of the New York Academy of Sciences.

[35]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[36]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[38]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Miller,et al.  Lack of expression of aminoacylase-1 in small cell lung cancer. Evidence for inactivation of genes encoded by chromosome 3p. , 1989, The Journal of clinical investigation.

[40]  J. Bishop,et al.  The expression of three abundance classes of messenger RNA in mouse tissues , 1976, Cell.

[41]  D. Sidransky,et al.  PGP 9 . 5 Methylation in Diffuse-Type Gastric Cancer , 2006 .

[42]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[43]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[44]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[45]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.